Why Amyris Fell 11% in September

Shares of Amyris (NASDAQ: AMRS) fell 11% in September, according to data from S&P Global Market Intelligence, after it was accused in a lawsuit of patent infringement and misappropriating trade secrets.

Specialty ingredients biotech Amyris, which develops sustainable ingredients for the clean health and beauty markets, as well as for flavors and fragrances, started the month on a positive note after announcing it had successfully scaled up commercial production of cannabigerol (CBG), a molecule developed from Cannabis sativa L., or hemp.

Image source: Getty Images.

Continue reading

Source Fool.com